ArticleIrish journal of medical science2026
Longitudinal serum uric acid trajectories and chronic kidney disease progression.
Article in Irish journal of medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFor patients with chronic kidney disease (CKD), the causal relationship between serum uric acid (SUA) levels and clinical outcomes remains controversial. This study aimed to investigate the association between longitudinal trends in SUA levels and CKD progression, taking related clinical parameters into account for patients with CKD.
methodsAdult patients with CKD who were followed for at least 12 months and were not receiving renal replacement therapy (RRT) at the start of follow-up were eligible to be involved in the study. SUA levels of the patients were recorded at three time points (baseline, median, and final). A priori threshold of 20% change was used to categorize SUA levels changes. Patients with a ≥ 20% increase in both intervals were classified as "increasing," those with a ≥ 20% decrease as "decreasing," those with < 20% change as "stable," and those with an increase in one interval and a decrease in the other as "non-monotonic". Univariate and multivariable binary logistic regression analyses were performed to assess the association of SUA levels with CKD progression.
result478 patients met the inclusion criteria. They were 67.3 ± 12.3 years old and 53.3% of them were males. The mean clinical follow-up duration was 60.6 ± 28.1 months. At the end of follow-up, 6.7% of patients initiated dialysis (n = 32), 37.4% experienced rapid progression (n = 179), and 2.3% died (n = 11). SUA trajectory patterns were as follows: 11.5% increasing, 5.0% decreasing, 3.6% stable and 79.9% non-monotonic. Trajectory with an increasing pattern were more frequent in rapid progressors than non-rapid progressors (15.6% vs 9.0%, p = 0.002). Having a stable SUA was also protective from rapid progression (p = 0,043). SUA measured at individual time points and use of urate-lowering therapy were not independently associated with rapid CKD progression or dialysis initiation.
conclusionsDynamic changes in SUA levels over time, rather than isolated measurements, may be associated with CKD progression, suggesting that longitudinal SUA trajectories may provide more meaningful prognostic information in patients with CKD.
Indexed as
Identifiers
42776458What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.